Stockscreener 앱 받기
7.78
5.35%
0.39
Cartesian Therapeutics Inc 주식(RNAC)의 최신 뉴스
Cartesian Therapeutics Inc (RNAC) - MSN
Cartesian Therapeutics Announces New Employment Inducement Grants - The Manila Times
Five new Cartesian hires get stock options priced at $6.22 - Stock Titan
CARTESIAN THERAPEUTICS, INC. (RNAC) - MSN
RNAC Reiterated by Cartesian Therapeutics -- Price Target Mainta - GuruFocus
Wedbush Reiterates Outperform Rating for Cartesian Therapeutics (NASDAQ:RNAC) - MarketBeat
Cartesian Therapeutics (NASDAQ:RNAC) Posts Quarterly Earnings Results - MarketBeat
Cartesian Therapeutics, Inc. Q1 2026 Financial Report: Forward-Looking Statements, Risks, and Financial Results - Minichart
Mizuho Securities Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Cartesian Therapeutics Reports Q1 2026 Financial Results and Advances Descartes-08 Clinical Trials in Autoimmune Diseases - Minichart
Cartesian Therapeutics, Inc. (RNAC) reports Q1 loss, lags revenue estimates - MSN
Myasthenia Gravis Market: Fast-Growing Therapeutics Outlook by 2034 – DelveInsight | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Hoffmann-La Roche, Janssen Research & Development, LLC - Barchart.com
Cartesian Therapeutics, Inc. (RNAC) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
8-K: Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updatemoomoo - Moomoo
Cartesian Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Cartesian Therapeutics posts first quarter 2026 financial results and issues business update - Traders Union
Cartesian Therapeutics (RNAC) widens Q1 loss as R&D rises but cash tops $120M - Stock Titan
Deeper Q1 loss as Cartesian (NASDAQ: RNAC) funds Descartes-08 trials - Stock Titan
Cartesian Therapeutics (RNAC) Projected to Post Earnings on Thursday - MarketBeat
Is Cartesian Therapeutics (RNAC) 1371.4% Overvalued After Q1 202 - GuruFocus
Cartesian Therapeutics | DEFA14A: Others - Moomoo
Cartesian Therapeutics | DEF 14A: Definitive information statements - Moomoo
Form DEFA14A Cartesian Therapeutics, - StreetInsider
Executive pay, director votes and auditor for Cartesian Therapeutics (NASDAQ: RNAC) - Stock Titan
RNAC Technical Analysis | Trend, Signals & Chart Patterns | CARTESIAN THERAPEUTICS INC (NASDAQ:RNAC) - ChartMill
Cartesian Therapeutics: A Phase 3 mRNA CAR-T Bet - Seeking Alpha
Is Cartesian Therapeutics (RNAC) stock a good pick for capital allocation | Q4 2025: EPS Misses ViewsDebt Analysis - Xã Thanh Hà
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Cartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock? - Yahoo Finance
Cartesian Therapeutics (RNAC) Stock Underweight (Underperforming) 2026-04-20Viral Momentum Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Cartesian Therapeutics (RNAC) Stock Abandons Cartesian Therapeutics (RNAC) Stock (Eye on Rally) 2026-04-18Vega Volatility - UBND thành phố Hải Phòng
Cartesian Therapeutics (NASDAQ:RNAC) Trading 10.3% HigherTime to Buy? - MarketBeat
Cartesian Therapeutics (RNAC) Stock Prediction: What's Next (Drops Sharply) 2026-04-15Community Risk Signals - Cổng thông tin điện tử tỉnh Lào Cai
Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight - GlobeNewswire Inc.
Published on: 2026-04-14 00:35:15 - baoquankhu1.vn
Needham Virtual Healthcare Conference features Cartesian Therapeutics fireside chat on cell therapy - Traders Union
Chart Watch: What chart patterns are forming on Cartesian Therapeutics IncGap Up & Long-Term Growth Plans - baoquankhu1.vn
Today's Analyst Ratings: Needham Reiterates Buy Rating for RNAC - GuruFocus
If You Invested $1,000 in Cartesian (RNAC) - Stock Titan
Trust linked to Cartesian Therapeutics (RNAC) converts preferred into common - Stock Titan
Trust linked to RNAC holder Kalayoglu converts preferred into 758,001 common shares - Stock Titan
Cartesian Therapeutics | 4: Statement of changes in beneficial ownership of securities-10% Owner Kalayoglu Murat - Moomoo
Near-20% holder updates Cartesian Therapeutics (RNAC) stake and board role - Stock Titan
RNAC SEC FilingsCartesian 10-K, 10-Q, 8-K Forms - Stock Titan
Is Cartesian Therapeutics (RNAC) Stock Good for Beginners | Price at $6.26, Down 2.03%Community Chart Signals - Cổng thông tin điện tử tỉnh Lào Cai
Published on: 2026-04-01 20:53:55 - baoquankhu1.vn
Big Money Moves: Should I invest in Cartesian Therapeutics Inc before earningsEarnings Summary Report & Smart Allocation Stock Tips - baoquankhu1.vn
RNAC Technical Analysis & Stock Price Forecast - Intellectia AI
Inflation Data: Does Cartesian Therapeutics Inc have declining or rising EPSMarket Weekly Review & Technical Buy Zone Confirmation - baoquankhu1.vn
Cartesian Therapeutics Announces Board Member Murat Kalayoglu Resignation - The Globe and Mail
Merger Talk: Will Cartesian Therapeutics Inc outperform the market in YEAR2026 EndofYear Setup & Entry Point Confirmation Signals - baoquankhu1.vn
Cartesian Therapeutics board member Murat Kalayoglu to resign effective March 31 - Investing.com UK
Cartesian Therapeutics board member Murat Kalayoglu to resign effective March 31 By Investing.com - Investing.com South Africa
Murat Kalayoglu to Resign from Cartesian Board, Leaving Science & Technology Committee - TradingView
Board member Murat Kalayoglu to leave Cartesian Therapeutics (RNAC) board March 31, 2026 - Stock Titan
Treasury Yields: Why is Cartesian Therapeutics Inc stock going down2026 Volume Leaders & Safe Capital Investment Plans - baoquankhu1.vn
Energy Moves: Is Cartesian Therapeutics Inc benefiting from interest rate changesMarket Activity Recap & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
0.78%
3.01%
자본화:
|
볼륨(24시간):